Revolutionizing
Type 2 Diabetes Management

Introducing

DAPALINA®

Unmatched Glycemic Control with **Dual Mechanism**

Worldwide
Novel Combination,
Launched in Korea in July 2024

Key Features:

- **Combination Therapy:**
  Harnessing the strengths of Dapagliflozin and Linagliptin.

  – Dapagliflozin (SGLT2 Inhibitor):
  Reduces glucose reabsorption in the kidneys, promoting glucose excretion.

  – Linagliptin (DPP–4 Inhibitor):
  Enhances insulin secretion and reduces glucagon levels.



T2DM, Type 2 Diabetes Mellitus; **SGLT2i,** sodium–glucose cotransporter 2 inhibitors; **DPP4i,** dipeptidyl peptidase–4 inhibitor;
References, Chadha M, et al. Diabetes Ther 2022;13(5):1097–1114

Clinical Excellence

- **Proven Efficacy:**
  Significant HbA1c reduction in patients inadequately controlled with metformin and linagliptin.

Study Highlights:

– Double–blind, placebo–controlled trial:
24 weeks of robust clinical data across 30 Korean hospitals.

– Significant Results:
Achieved superior glycemic control with an additional –0.88% reduction in HbA1c compared to the Meformin/Linagliptin treatment group (p 〈 0.0001).

The change in HbA1c from baseline to weeks 12–24



*LS Mean ± SE, 1Difference between LS Mean
HbA1c, hemoglobin A1C

References, Data on file. Clinical Phase III trial in Korea. AJU–A51(2023)

Dapalina® + Metformin
Linagliptin + Metformin

Safety Profile

- **Tolerability:**
  Well–tolerated with a safety profile consistent with individual components.
- **Adverse Events:**
  Minimal and manageable, enhancing patient adherence.

Who Should Consider DAPALINA®

- Patients with Type 2 Diabetes who need better glycemic control despite metformin and linagliptin therapy.
- Individuals seeking a novel, effective, and convenient treatment option.

Patient Convenience

- **Once–Daily Dosing:**
  Simplifies therapy and improves compliance.
- **Flexible Administration:**
  Can be taken with or without food.
- Suitable for Administration in Patients with CKD (eGFR ≥ 45 mL/min/1.73m2)

Additional Benefits

- **Weight Loss:**
  DAPALINA® demonstrated a significant weight reduction (–2.4 kg) over 24 weeks.

Change in weight from baseline to week 24



- **Waist Circumference Reduction:**
  Significant reduction in waist circumference compared to baseline at 24 weeks.

Change in waist circumference from baseline to week 24



- **Fasting Plasma Glucose (FPG) Reduction:**
  DAPALINA® Tab significantly reduced fasting plasma glucose (FPG) compared to the control group at 12 weeks of treatment, and this decrease was maintained steadily until week 24. (p<0.0001, p<0.0001)

The change in fasting plasma glucose(FPG) from baseline to week 24



- **Insulin Resistance Improvement:**
  DAPALINA® Tab significantly improved insulin resistance markers at the 24–week treatment.

Change in HOMA–IR | **Change in QUICKI**